Corpus ID: 16508664

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

@article{Selvakumaran2003EnhancedCC,
  title={Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.},
  author={Muthu Selvakumaran and Debra A Pisarcik and Rudi Bao and Anthony T. Yeung and Thomas C. Hamilton},
  journal={Cancer research},
  year={2003},
  volume={63 6},
  pages={
          1311-6
        }
}
  • Muthu Selvakumaran, Debra A Pisarcik, +2 authors Thomas C. Hamilton
  • Published in Cancer research 2003
  • Biology, Medicine
  • Ovarian cancer is the leading cause of death among women from gynecological malignancies inthe United States. Resistance to the chemotherapeutic agent cisplatin isa major limitation for the successful treatment of ovarian cancer. In an effort to overcome the cisplatin resistance problem in ovarian cancer treatment, we have sought to enhance cisplatin cytotoxicity by perturbing the nucleotide excision repair (NER) pathway. The NER pathway is responsible for repairing cisplatin bound to DNA… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 172 CITATIONS, ESTIMATED 62% COVERAGE

    Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro.

    VIEW 7 EXCERPTS
    CITES METHODS & BACKGROUND
    HIGHLY INFLUENCED

    Establishment of a New Human Glioblastoma Multiforme Cell Line (WJ1) and Its Partial Characterization

    VIEW 3 EXCERPTS
    CITES METHODS & BACKGROUND
    HIGHLY INFLUENCED

    FILTER CITATIONS BY YEAR

    2001
    2019

    CITATION STATISTICS

    • 10 Highly Influenced Citations

    • Averaged 8 Citations per year from 2017 through 2019

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 38 REFERENCES

    Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

    VIEW 1 EXCERPT